Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

21 Apr 2022

Aptar Pharma Q&A on trends and challenges in nasal drug delivery

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
4 Apr 2022

Why it is time to think differently about Nasal delivery of Biologics

Publications, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
25 Feb 2022

Aptar Pharma discusses intranasal administration for CNS therapeutics

Webinars, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation, Market Insights

Read More
15 Feb 2022

New solutions for pre-clinical discovery in respiratory healthcare

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 … 13 14 15 16 17 … 27

How Can We Help?

Back To Top